0001558370-23-005925.txt : 20230414 0001558370-23-005925.hdr.sgml : 20230414 20230414083306 ACCESSION NUMBER: 0001558370-23-005925 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20230414 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230414 DATE AS OF CHANGE: 20230414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOLIGENIX, INC. CENTRAL INDEX KEY: 0000812796 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 411505029 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14778 FILM NUMBER: 23819847 BUSINESS ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE B-10 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-538-8200 MAIL ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE B-10 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: DOR BIOPHARMA INC DATE OF NAME CHANGE: 20020329 FORMER COMPANY: FORMER CONFORMED NAME: ENDOREX CORP DATE OF NAME CHANGE: 19960916 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19920703 8-K 1 sngx-20230414x8k.htm 8-K
0000812796falseDE00008127962023-04-142023-04-14

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):  April 14, 2023

 

Commission File No. 001-14778

 

Soligenix, Inc.

(Exact name of small business issuer as specified in its charter)

 

DELAWARE

 

41-1505029

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification Number)

 

 

 

29 Emmons Drive,

Suite B-10

Princeton, NJ

 

08540

(Address of principal executive offices)

 

(Zip Code)

​

(609) 538-8200

(Issuer’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $.001 per share

 

SNGX

 

The Nasdaq Capital Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

w

​

​

​

​

​

Item 8.01. Other Events.

​

On April 14, 2022, Soligenix, Inc. (the “Company”) issued a press release announcing the outcome of a Type A Meeting with the United States Food and Drug Administration (the “FDA”).  During the Type A Meeting, representatives of the Company and the FDA discussed the contents of a refusal to file letter previously issued by the FDA regarding the Company's new drug application for HyBryte™ (synthetic hypericin sodium) in the treatment of early stage cutaneous T-cell lymphoma (CTCL), a rare cancer, where it successfully demonstrated statistically significant results in a Phase 3 clinical trial (Study HPN-CTCL-01; also referred to as the FLASH study).  A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

​

Safe Harbor for Forward-Looking Statements

​

Certain statements contained in this report may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the 1934 Act. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “predicts,” “plans,” “expects,” “anticipates,” “believes,” “goal,” “target,” “estimate,” “potential,” “may,” “might,” “could,” “see,” “seek,” “forecast,” and similar words. Forward-looking statements are based on the Company’s current plans and expectations and involve risks and uncertainties which are, in many instances, beyond the Company’s control, and which could cause actual results to differ materially from those included in or contemplated or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks, uncertainties and factors detailed in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including in the Company’s Annual Report for the year ended December 31, 2022 on Form 10-K, which was filed with the SEC. As a result of such risks, uncertainties and factors, the Company’s actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this report as of the date hereof and assumes no obligations to update the information included in this report or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

​

​

Item 9.01. Financial Statements and Exhibits.

​

(d)     Exhibits.

Exhibit No.

    

Description

99.1

 

Press Release dated April 14, 2023.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

​

​

2

​

​

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

 

Soligenix, Inc. 

​

​

April 14, 2023 

By:

/s/ Christopher J. Schaber 

 

 

Christopher J. Schaber, Ph.D.

​

​

President and Chief Executive Officer

​

​

(Principal Executive Officer)

​

​

​

3

 EX-99.1 2 sngx-20230414xex99d1.htm EX-99.1

EXHIBIT 99.1

Graphic

Graphic

​

Soligenix Provides Regulatory Update on HyBryte™

​

Princeton, NJ – April 14, 2023 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company convened a Type A Meeting with the United States (U.S.) Food and Drug Administration (FDA). During the Type A Meeting, representatives of the Company and the FDA discussed the contents of a refusal to file (RTF) letter previously issued by the FDA regarding the Company's new drug application (NDA) for HyBryte™ (synthetic hypericin sodium) in the treatment of early stage cutaneous T-cell lymphoma (CTCL), a rare cancer, where it successfully demonstrated statistically significant results in a Phase 3 clinical trial (Study HPN-CTCL-01; also referred to as the FLASH study).

​

In order to accept an NDA filing for HyBryte™, the FDA is requiring positive results from a second clinical study in addition to the Phase 3, randomized, double-blind, placebo-controlled FLASH study previously conducted in this orphan indication.  The FDA indicated that it is open to engaging in protocol discussions regarding the second clinical study.  Based on the feedback, the Company has decided to collaboratively engage in discussions with the FDA in order to define the protocol and evaluate the feasibility of conducting the additional clinical trial.

​

“While we are very disappointed by this delay, Soligenix and its clinical investigators remain committed to working with the FDA and advancing HyBryte™ to market for patients suffering with CTCL,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. “The Phase 3 FLASH study was the largest double-blind, randomized, placebo-controlled clinical trial ever conducted in the CTCL population. While we are surprised that the FDA did not accept our submitted NDA for filing and review, it was very clear that the FDA’s thinking has evolved in evaluating CTCL therapies since our initial protocol discussions on Study HPN-CTCL-01 and that another Phase 3 study will be required to support an NDA for HyBryte™. During the Type A meeting, we discussed elements of protocol design for the additional confirmatory study and look forward to collaborating with the FDA to advance these discussions as quickly as possible to have a reasonable study design to meet the FDA’s requirements.”

About HyBryte™

​

​

​

HyBryte™ (research name SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation.  The active ingredient in HyBryte™ is synthetic hypericin sodium, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by visible light approximately 24 hours later.  The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging drugs and other phototherapies that are dependent on ultraviolet exposure.  Combined with photoactivation, hypericin has demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients.  In a published Phase 2 clinical study in CTCL, patients experienced a statistically significant (p=0.04) improvement with topical hypericin treatment whereas the placebo was ineffective.  HyBryte™ has received orphan drug and fast track designations from the FDA, as well as orphan designation from the European Medicines Agency (EMA).

The recently published Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study enrolled a total of 169 patients (166 evaluable) with Stage IA, IB or IIA CTCL. The trial consisted of three treatment cycles. Treatments were administered twice weekly for the first 6 weeks and treatment response was determined at the end of the 8th week of each cycle. In the first double-blind treatment cycle, 116 patients received HyBryte™ treatment (0.25% synthetic hypericin) and 50 received placebo treatment of their index lesions. A total of 16% of the patients receiving HyBryte™ achieved at least a 50% reduction in their lesions (graded using a standard measurement of dermatologic lesions, the CAILS score) compared to only 4% of patients in the placebo group at 8 weeks (p=0.04) during the first treatment cycle (primary endpoint). HyBryte™ treatment in the first cycle was safe and well tolerated.

In the second open-label treatment cycle (Cycle 2), all patients received HyBryte™ treatment of their index lesions. Evaluation of 155 patients in this cycle (110 receiving 12 weeks of HyBryte™ treatment and 45 receiving 6 weeks of placebo treatment followed by 6 weeks of HyBryte™ treatment), demonstrated that the response rate among the 12-week treatment group was 40% (p<0.0001 vs the placebo treatment rate in Cycle 1). Comparison of the 12-week and 6-week treatment groups also revealed a statistically significant improvement (p<0.0001) between the two groups, indicating that continued treatment results in better outcomes.  HyBryte™ continued to be safe and well tolerated. Additional analyses also indicated that HyBryte™ is equally effective in treating both plaque (response 42%, p<0.0001 relative to placebo treatment in Cycle 1) and patch (response 37%, p=0.0009 relative to placebo treatment in Cycle 1) lesions of CTCL, a particularly relevant finding given the historical difficulty in treating plaque lesions in particular.

The third (optional) treatment cycle (Cycle 3) was focused on safety and all patients could elect to receive HyBryte™ treatment of all their lesions. Of note, 66% of patients elected to continue with this optional compassionate use / safety cycle of the study. Of the subset of patients that received HyBryte™ throughout all 3 cycles of treatment, 49% of them demonstrated a positive treatment response (p<0.0001 vs patients receiving placebo in Cycle 1). Moreover, in a subset of patients evaluated in this cycle, it was demonstrated that HyBryte™ is not systemically available, consistent with the general safety of this topical product observed to date. At the end of Cycle 3,

2

​

​

​

HyBryte™ continued to be well tolerated despite extended and increased use of the product to treat multiple lesions.

Overall safety of HyBryte™ is a critical attribute of this treatment and was monitored throughout the three treatment cycles (Cycles 1, 2 and 3) and the 6-month follow-up period.  HyBryte's™ mechanism of action is not associated with DNA damage, making it a safer alternative than currently available therapies, all of which are associated with significant and sometimes fatal, side effects.  Predominantly these include the risk of melanoma and other malignancies, as well as the risk of significant skin damage and premature skin aging.  Currently available treatments are only approved in the context of previous treatment failure with other modalities and there is no approved front-line therapy available.  Within this landscape, treatment of CTCL is strongly motivated by the safety risk of each product.  HyBryte™ potentially represents the safest available efficacious treatment for CTCL.  With very limited systemic absorption, a compound that is not mutagenic and a light source that is not carcinogenic, there is no evidence to date of any potential safety issues. 

The Phase 3 CTCL clinical study was partially funded by the National Cancer Institute via a Phase II SBIR grant (#1R44CA210848-01A1) awarded to Soligenix, Inc.  In addition, the FDA awarded an Orphan Products Development grant to support the evaluation of HyBryte™ for expanded treatment in patients with early-stage CTCL, including in the home use setting.  The grant, totaling $2.6 million over 4 years, was awarded to a prestigious academic institution that was a leading enroller in the Phase 3 FLASH study.

About Cutaneous T-Cell Lymphoma (CTCL)

​

CTCL is a class of non-Hodgkin's lymphoma (NHL), a type of cancer of the white blood cells that are an integral part of the immune system.  Unlike most NHLs which generally involve B-cell lymphocytes (involved in producing antibodies), CTCL is caused by an expansion of malignant T-cell lymphocytes (involved in cell-mediated immunity) normally programmed to migrate to the skin.  These malignant cells migrate to the skin where they form various lesions, typically beginning as patches and may progress to raised plaques and tumors.  Mortality is related to the stage of CTCL, with median survival generally ranging from about 12 years in the early stages to only 2.5 years when the disease has advanced. There is currently no cure for CTCL.  Typically, CTCL lesions are treated and regress but usually return either in the same part of the body or in new areas.

CTCL constitutes a rare group of NHLs, occurring in about 4% of the approximate 700,000 individuals living with the disease.  It is estimated, based upon review of historic published studies and reports and an interpolation of data on the incidence of CTCL that it affects over 25,000 individuals in the U.S., with approximately 3,000 new cases seen annually.

About Soligenix, Inc.

​

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase

3

​

​

​

3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin sodium (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203).

​

Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, and SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease, and our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).

For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.

This press release may contain forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, such as experienced with the COVID-19 outbreak. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in healthcare practice, third party reimbursement limitations and Federal and/or state healthcare reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that a marketing authorization from the FDA or EMA will be successful. Notwithstanding the result in the HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 1/2 proof-of-concept clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Further, there can be no assurance that RiVax® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax®. Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K.

4

​

​

​

Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

​

Company Contact:

​

Jonathan Guarino, CPA, CGMA

Senior Vice President and Chief Financial Officer

(609) 538-8200 | www.soligenix.com

Soligenix, Inc.

29 Emmons Drive, Suite B-10

Princeton, NJ 08540

5

​

 GRAPHIC 3 sngx-20230414xex99d1001.jpg GRAPHIC begin 644 sngx-20230414xex99d1001.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" !\ ;P# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z*** "B MBB@ HHKSOXC?&G0?AZC0S2F^U3;E+&W(W>V\]$'Z^UYF,=NGJ3DY(' MJQ_"OFZ&>5 H-P7VY/EC\M&W_5SZ3$9'2RY)9AB%&;^Q!?'GX=>!HFM-'B%QMX\O2+4 M+'G_ 'CM!^HS6 /VN["23;#X9O)%]?M"9_( UN^(,OH)0Q%>+E_=NU^%SGCP M]F->\\/AYH6M_I#'C?-$'0?BIS^E>I:'XC MTSQ+:?:M+O8+ZW/\<$@;'L?0_6O5PN98/&Z8>JI/LGK]VYY>+RW&X'7$TG%= MVM/OV-6BBBO2/-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBJT]S'9P233.L4,:EG=C@* ,DD]A2;LKL-]"'5M6L]"TV>^OITM; M6!2\DLAP%%9'@GQ4_C/2WU1+"6QL9)2+1IS\\\7&)"N/E!.<#/3FO%+GQ)-^ MT+\28-#M3)'X.TYOM%P.5^T@' +?[QX ],FO0/CA\14^&_@X6]@PAU2\4P6: MH!^Z48W.!VP#Q[XKY:.<1J1JXV]L/3NK_P [ZV\ELN[\CZF633IRI8+EOB*E MG;^2/GYO=]DO,Y+XZ?'IO#TLWA[PY,/[2'RW5\N#]G]43_;]3_#]>GDGPE^% M=_\ %/77GN7D32(7W7EX2=TC=2BL$5MX0MKIFGP%W<]< 99R>Y/)^M?$8"C6XGQON6-?/\ \=?M%ZRRO.8M(B?YL96UM_8 ??;'KD_2D@ M@U;]HSXHR2,9(-+BZG/%K; \ =1O;^>3VKZNT#0+#POI,&FZ;;I;6<"[4C08 M_$^I]Z]FE2J<25&DW#!P=DEISV_3^M]O&JU:?#---I5,9-7;>O)?]?S]-_/? M"?[./A'PY%$UW:'6[M>6EO3E"?:,?+CZ@UZ38:18Z7&([.SM[6,=%@B5!^0% M([VZF MM_ ?A:QTFRY"7NM$SSL/[WEHRJA]B6K]*RO(%RVP-%1CWV_'=GYKF6>SG+FQ MM9R?:]_PV1^DUWI]M?1F.YMHKA#U61 P/X$5R4_PFT&&\;4-(A?P]J?_ #\Z M6WE _P"]']QA[%:_*2X_X* _'S4V:6+Q:(HQVM=)M=H_$Q'^=:>@?\%)OC=I M,RMY6X4JUES5%"37K=>CMH>/1XDC0;5.4HI[] MGZJ]FO)GZT:-+J<<+0:FB231]+J#"I,/7;U4^HY'H:UQTKQO]E/XV:C\?OA# M8^+M5TVVTJ]FGF@>"TD9H_W;E=PWM&K&NE5 MCL]0HHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>#_ M +4/Q _LG0H/#=I(5N]0'F7!4X*P@X _X$P_)37N (]1D3;=ZNWVAB>HC'$8_+G_@5?/G MQN\8MXT^(FHSH^ZSM&-I;#=QM0D$CZMN-?7/B:ZC\%?#O49;;]W'I^G,(<<8 M*IA?UQ7P27.TL3D@9)]:^4XH:R_!8;*Z>R5WYV_S=V?6\*)YCC\5FM3=NR\K M_P"221]+_LI>#5BL-0\2SQ_O9V-K;D]D7!B+X?^'?A^R VE+1&?\ WV&YOU)KRO\ :I@:_N?! MMB/]7<7;H?J3&O\ (U]-6H/*^''3I_$XJ_K-I/\ ,^8H8A9KQ*JM3X5)V]() MM?E<[#]GSP6GA+X?VD\D>R^U,"[F)ZX(^1?P7'ZUZE5>TA2VMHHD 1$0* .@ MXQ5BOL,%A88+#4\/3VBDOZ]=SXS&XJ>-Q-3$U-Y-O_@?+8_&W]OKXK:A\2/V MA-=T^69_[)\.2MI=E;;OE4IQ*^.FYG!Y] H[5Z]_P3M_95\+_$K2;_Q]XQL( MM9M[:[-IIVF7 W0;D +RR+T?DX /'!X/&/"OVX/A_>^ /VD_%R7,12VU:Y.J MVDI'RR1S'<<'OAMRGW%>F?L$_M=:5\$9[WP=XO=K;PQJ5R)[?4@I864Y 4B0 M#GRVP#D?=.<\'(_5Z\*CRJ,<'V6V]NMC\VHR@LQD\5W>_P"!^IVGZ-8:1:+: MV-E;V=JHVK#!$J(!Z 5YE\5/V6?AE\8K*6/Q!X5LEO'!VZG81BVNT/]X2* M 3CT;(]J].TO5;/6K""^T^Z@OK.= \5Q;R!XY!V((X(J]7YU"K4I2YH2:9]Q M*G"I'EDDT>1?LT_!.7X _#IO"3:@NJ6\-]<36]P%*LT3N64,.S '!QQ7KM%% M*I4E5FZDWJQTZ<:45".R"O /C7^VU\,/@A=SZ=J&J2ZWKL7#Z7HR":2,^DCD MA$/L6S[5\W?M[?MIW^F:K>_#;P'J#VC09BUC5K9L2;N\$;#E<=&8<]NQSQO[ M(?[ J_%31[7QM\0Y[BWT*[Q-9Z7 Y2:\7/\ K)'ZJA[ (/AVT4!/,VF:GO8#V1XP#_P!]"OLOPQ^S]\-O!UA'::3X M%T&UA08!-A')(W^\[ LWXFN>^)'[)'PG^*&GRP:IX.TVSN74A;_2H%M+E#V( M:,#./1@1[4EBLJ;Y7AVEWN[_ )@\/F*]Y5DWVMI^1-\%?VI_AW\>H OAK60F MJ!=TFDWP\F[3U^3)##W4L*]?K\6?VEOV;O$G[*GCZUEL[VYFT:>3SM)UN F* M0$?PL5^[(OMUZCK7W9^P?^UC+\;O#DGA?Q/=B3QEI:;A,PVF]@Z!_P#?'1OP M/>C'97"G16+PDN:F_O7]=>P\'F,IU?JV)CRS_,^K=1N9K2QGFM[5[V=$+);1 MLJM(1V!8@#/N:^/_ !!_P4\\$>%];O=(U3P5XKL]2LIF@G@DCM@T;J<$?Z[] M:^S:_%K]NNUBM?VH/&:QH$#S+(V.,L5!)J,FPE#&594ZROI=:V+S7$UL+3C4 MI/K8_5SX'_&*/XX^#H_$]GX?U/0]+N&_T4ZIY8>=1U=51VPON>M>DUYO^SK; M16?P-\#Q0H$C72H,*.WRUZ17BUU%59*"LDV>K1.XI5#QG2Y,@ M^V"*=!1E5C&:NFT*NY1IR<79I'A/AG_@IIX*\8^(+#0]'\%>*[W4[Z98+>!$ MMLNYZ#_7 VTSJ"T+,&*'TR./RK\&#Q#(G_$QU.$C= M9J?^6:'M(1U/4#WKYR_93_8PUS]I&\?Q5XJO;S3_ F927O&8M=:A)GD(7SQ MZN<^V:O"Y7#V'UK&RY8=%U9&(S"?M?JV%CS3_!'O7BK_ (*Q:#:R/'X=\!:A MJ* X6;4[Y+;/OM19/YURT/\ P5IU42@R?#:R:/T35G!Q]3":^Q? O[)OPD^' MEI%#I?@;2)Y4 'VK48!>3L?7?+N(_#%=%K7P(^'/B&T>VU'P)X=NH6&,-I<( M(^C!01^!I_6LJB^6.';7=R_X(OJ^8RU=9)^B_P CP3]GG_@H-H_QX\>67A)O M"%]H>IW:.Z3"Z2XA^49.3M0_I7UL1VEA8.N T1.2I![$D?2OI<=*\W&O"NHI81-1MJGT9Z&$6(4&L2[N M_3L?*_Q>_;[\.?!+QK=^&?$_@KQ-!?0@.DD(MFBGC/W70^;R#[\UQG_#UKX< M?]"IXI_[XMO_ (]7D_\ P5?MHH_'W@J<*%DDT^=6<=6 =<5U'[!W[+GPP^*W MP6/B+Q9X6CUG5_[1FM_.ENIU78H7 V(X7N>U>_'"8"G@88NM!Z]GUU_R/$EB M<;/&2PU*2T[H[#_AZU\./^A3\4_]\6W_ ,>KZA^#/Q5LOC5\.],\7Z;97%A9 M7^\Q0717S%"L5YVDCMZUY?X@_8#^!^NZ=+;Q^#1IDK#"W5C>SI(A]1ER#]"" M*](^!7PK3X*?#;3O!\5^VI06#R"*X=-C,C.64,/49Y/>O&Q MWXGJ8:.-C4MB&G&W3N=%XU\1W7A/PU>ZK::-=Z_):H9?L%@R":11UV[V52<= MLU\DC_@JE\.ENO(F\*>*;8A]CF6*W'EG.#D"7/'?C/%?:94.A4@$$8(K\(_C M9HLA^-OCJRTZVDE6+5KQQ%"A8JHD9F.!V R:['QKG"LMM;W.7-,56PBA M*D]_(_^++TGPU?R[=/NYFXL9F/W23TC8_D>>YK]2%.0".E>9C\%/ UG3EMT M?='H8/%PQE)3COU79E>\FDM[:62*%KB55)6%2%+GT!/ S[FOD7Q?_P %*_!_ M@+Q/J/A[7O _BO3]7T^4PW%NT=L2C#G@B;!!!!![@U]AU^2O_!0G3X$_:WB5 M(U07-I9/+@#YF+LN3Z\ #\*Z\HPU'%UG2K*ZM?>QS9G7JX:DJE)];'Z:?";X MB/\ %3P98^)1H.H>'[6_7S;6WU/8)GB/W9-J,V >V3DCGH:\9^.'['/$O@_Q$T[1B:VNK46[P7$9XW*3*#U!!!&17TIIUM'9:?;6\*".&*)8 MT11@*H 'Y5^=_\ P5GMH1=?#J<*/M!6\3=WV_NJC+J-'%8Q4IQ]UWZ[:7+Q M]6KAL*ZD)>\K=-SZ6_9[_:]TG]I'6+VU\-^$M>M+*P0-=ZEJ @6"(MG8ORR% MF8X/ '0&NW^-GQD'P1\,MXAN_"^M>(-)A!-U+HJQ2-:K_?='=3M]USCO@5\Z M_P#!*^"-/@AXAG"!97UMD9QU($4>!^&XU]FW%M%=020RQK+%(I1T<95@>H/M M66-ITSV*=EI/G+P9Z ?Q*/3@?=K[*_P""??[2[?&#P"_A37KP2^*_#\:H M))7S)>6G1).>K+]UCU^Z3UKT<=EU%8:.,P=^1[I]/ZZG#@\=5=>6%Q/Q=/,^ MM+F1XH)'CA,\B@E8P0"Q],G@?C7R9X[_ ."CW@OX:>+]4\,^(/"'BFUUC39? M)N(HX[5U!P""&$_((((/'!KV/]H_X\Z1^SU\-;[Q)J!2>^8K#=A[JX(.U M1_LCEF/8 ^U?FM^RO\"-7_:^^,NK>)_%Y'KM=^1IC\75A4A0PS]]_D?IS\#?C);?'/P8GBG3 M] U70M+GD*6O]K)&CW"KP9$".WR9R,GJ0:]&'057T^PMM*L+>SL[>.UM+>-8 MH8(5"I&BC"JH' JS7A3<93;@K+HCV8*2BE-W84445!9Q'QDUMM ^&FOW M*';(UL8%/<&0A,CZ;LU\@?"ZV6[^)'AF)AE3J$+$?1L_TKZ9_:=G,/PNE0?\ MM;R%#].3_P"RU\S?"ZY6T^)'AF5CA1J$0)^K8_K7X]Q15YLYP]-[1Y?QE_PQ M^R\*4N3),346\N;\(_\ #GUM\>&*?"3Q&5ZF%%_.10?YU\0[=W!Z'BONWXMZ M8VK_ S\2VT8RYLG<#U*C=_[+7PBW*';U(XKGXWBUC:4NG)^3?\ F=' DT\# M5CUY_P TO\C]$],C$6G6L:]%C4#\A7D?[2EAC2/#>LXRNF:K$TGLC,,G\U6O M2_!FIIK'A/1[U#N$]I%("/=14?CKPQ'XQ\(ZKHTC!/M<#1JQ_A;JI_ @&OT_ M'4/K^7SIT]Y1NO5:K\4C\KP&(^H9C"K4VC*S]'H_P;-Z)M\:,.A I]<=\+]; MFU?PA:1WJ&+4['_0KV)OO+,GRM^> P]B*[&O2P]55Z4:L=FDSS:]*5"K*E+= M.QXS^TG^S)X;_:3\*)I^KEM/U>SRVG:Q H,MNQZJ0?O(>,K^(Q7Y2?'']E'X MA_ 2\F;7M(>[T56Q%K>G*TMHXS@;B!F,GT8#\:_<&J]S;17MN\-Q&DT,@VO' M(H96'H0>"*^CP&;5L#[B]Z'9_H>#COO;X(_\%.O"WBZX@TOX@:9_PB5[(0HU*V8S M63$_W^-T?/KN [D5V?QN_P"">'PW^*$=Q>^'[?\ X0C7GRPFTY/]%D;G[\'0 M#/=-OXU^9WQJ^ _B[X!^*&T;Q58>3ORUK>PG=;W2 _>C?'/N#@CN!7U,7EN= M:-6G]S_R9\[)8[*M;WA]Z_S1^Z6GZA;:M90WEE/'=6LZ"2*>%@Z.I&001P1B MN0^-_C[_ (5;\)O%'BD8\W3K)Y(0W3S3\L>?;WCF8M]BN&^X4ST5C\I7U(/KG[7_;YAFG_ &6/&7D G:L#/M_N M^TC4I&G_ +7U'SKV1B2609DD!/7D C\:_-8XXT& J M@8 K\;_ -@34+>P_:C\*?:"J"8311EO[QC8C\>#7[-#I7I<1SE[>%/HE^;_ M . <.117L9SZMBT445\D?3'DO[4'PFL_C+\%_$.A7$0:Z2!KNRDVY:.>,%E( M^O*_\"K\>O@=X\OOA!\8_#VNP,8WL;Y8KA2Y\CGI8P!OKL%?C[^WK_R=%XO_ -^/_P! %"O^P5!_Z"*]#KYFM_%GZL^@ MH_PX^B_(*\Q_:9_Y(#X[_P"P7+_*O3J\Q_:9_P"2 ^._^P7+_*JP_P#&AZK\ MQ5_X4O1GY<_\$^/^3HO#?_7.;_T&OUL^)?BZ/P%X!\0>(9,%=-LY+@ ]-P7Y M?UQ7Y)_\$^/^3HO#?_7.;_T&OTJ_;+2=_P!F;Q^+?._^SFSC^[N&:^HSN"J9 MC3@]FDOQ/G/C9IUG>3/+?^(M4!FD8DL-[9;! M]AD?E7[C^%/#&G^"_#>FZ'I4"V^GV$"6\,:C "J,9^O<_6OQB_8RU"#3OVF? M 00#@^M?'GU( MZBOA/]J;]LOXL_LW?$;^PCI/A;4]+NXOM-A>26EPCO'G!5P)\;@>"0 #7N_[ M('QMU[X_?"@^*O$%KI]G>->RVRQ::CI'M4#DAV8YY]:]&K@*U*@L2[;?\%8/^1V\"_P#7A?\%#K^"9!+%+K5^CHW(93O M!!]0:_62OR@^"'_*16Z_[#M]_P"SUZN4:4L3_@9YV:?Q*'^(YS]MO]E&Z^ ? MB\Z]HD3R>#-6F9X'5?\ CRE))\@XZ#J5/IQVY^J_V!/VNH_B3HMK\/?%%PL? MB;3H0EA=2/\ \?T"C[IS_P M%&/J/<<_6'Q%\ Z-\3_!^I>&=>M$O-,U"(Q2 M(PR5]&7T8'D'L17XO?^*OV6/B^;)I;FTGLKC[5I&K1Y7SXPV4=2.,C@, M.Q_"O3PM6&5C_P"C'K[K_9-_:2TW]HGX>6]T\\47BFP18M5L0-K*_02JO]QNOL:U8UL'&I!W3:/U= MM_\ 41_[H_E7YV_\%:?^/CX<_2]_]I5^B5O_ *B/_='\J_.W_@K3_P ?'PY^ ME[_[2KBR3_?X?/\ )G5F_P#N4_E^:/1/^"5__)"=>_[#LG_HF*OM$=*^+O\ M@E?_ ,D)U[_L.R?^B8J^T1TKGS7_ 'ZKZFV6_P"Z4_0X#XW?"'1OCC\.M5\) MZTF(;I"T%RH!DMIEY25,]P?S&1T-?CJDGC+]D/X['K9Z_H%WP<$0W<)_G'(A M_7'45^X%[>P:=:S75S*D-O"I>25SM5% R23VP*_(#]LCXP0_M/?'*UM?!6D- MJ-OIZ'3K&>SA+W&HG<6+@ F3_%7L\/U*DI3H25Z;6O9?\ #_\ !/+S MJ$(J%:+M-/3S_P"&)O'7C?QG_P %!OCUH^DZ99'3+"-/+MK0MYD6G0<&:>5@ M "3@9/LBCGK^H_P:^$6A?!'X?Z;X4T"+;:6JYEN'4"2YF(&^5\?Q,?R ' K M\J/V'_VB8/V?OBJT.M(D?AO6PEGJ$[(/,M""=DH/4*&/S#TR<9 K]CK6YBO+ M:&X@E2>"5 \5)E^JL"/Y5]V_$W0?^$D\ :_IR)OEEM7:-?5U^91_WTHKX,K\5XUI2IXZ MG66SC^*;_P T?MW U6-3+ZE![QE^#2_R9^AME*M4T>4$&TG=%)_B3.5;\5(-?4G[-/C$>(? *:=*^Z\TEOLY! MZF,\QG\LC_@-VX$%Z!W3.$?\"<'V(]*]WB"C_;. M44LPHZN*N_1Z2^YK[DSP.':[R7.*V75G93=EZK6+^:?XHZ;]F+Q.NM_#U=.= M\W.ERF$J>OEDED/Y$C_@->Q5\0_!'Q\? 'C>WGN)=FF7F+>Z!^ZJD_*Y_P!U MN_H37VVCK(BLIW*>01WKW.%I^Z_3H_N_%,\+BO+G@J^_\ !HQTT);77WU.V81-<+LNXL?++M^X_LPZ9[CZ"M2YGBLK>6>9Q'#& MI=W;@*H&23] *GJ-T61"C ,K @@\@CN*^MA"-._*M]3Y".ZM9D#Q3PN&1U/0@C@@YZBK=?CW=?'[XD_L@?&3Q;X4\.ZN9] T[5I MPFB:DAFM&B+EDV@_-'E2#\A'XU]*>"/^"K?A.^MXT\6^#]5TFXQ\TNDR1W41 M/J QC8#VYKZ2MDN*@E.BN>+U5M_N_P"'/"I9MAY-PJ/EDNY]X5\H?\%)M(TF M]_9ONKN_$8O;._@:QD;[PD;(95/NH)(_V?:L#Q#_ ,%3/A;86+OI.C^(M7O, M?+"]M';QY]&=G./P4U\-?M!?M/\ C;]J'Q%:0WL)MM+CEVZ?H.G*756/&3QN MDD/3/Y 5TY9E6*6(C5J1Y%%WU.;,,QP[HRIP?,WIH<7\!_#]WXH^,_@G3K%2 MUS+J]LPV]0J2!V/X*I/X5^W/Q.\#P_$7X;>(/"TY 74K&2V5VZ*Y7Y&/T8 _ MA7RO^PA^QK/\)XE\=>,[55\57,6VRL'Y-A$PY+=O,8=?0<=S7VM6>=8Z.(Q, M?8NZAU\R\IP.+Q8B[KW3P0JZ@ /O+V$N/^^OKU^-?@#^U%X\_9/\1W6C3V4]SHZSD:AX MMB80SS#QJT'^\CNOZ_ \[#SEE%>5.LOTU&RE;:>XWQ*ZG\ZH^//\ @I/\ M'_"ME*=%O;_Q;>@?)!8VDD*$]MTDH4 >X#?2OE%EV,N?M*?%BQ^#7P>\0^(;J98[C[.]O9QYPTEPZE4"^I'7Z"OR<_90^%E[ M\;?CWHEF8VDLX+H:EJ$N/E2-&W<_5L#'UKI/'?C_ .*O[>/Q(M[#3M,EFM(6 M/V32K0M]EL8SP9)9",9]6;Z =J_1_P#97_9DTK]F_P #BQ1XK[Q'>XDU+4E7 M'F-V1<\A%Z#UZU](G'),)*$G>M/IV_X8\%J6;8F,TOW<.O<]RBC6*-$0!44 M #L*_&+]O;_DZ+Q?_OQ_^@"OV?K\5/VX=5M]7_:<\:RVTBR1Q7(@9E.1N50# M^MK?8[J68X14XIU%LC[4KS']IG_D@/CO_ +!< MO\J^?/V;_P!I[QE^UA\89FM[1?"?@;0H3<36=M+YD]W(QQ&LLN!QU.U0![FO M=?VK-5M]&_9W\=W%RZI'_9KH-QQDG KF^K5,-BJ=*I\5UIVU-_K$,1AYU(; M6?S/S'_X)\?\G1>&_P#KG-_Z#7ZY>/?"T/CCP5KF@3X,6HVDEL=W0%E(!/T. M#7Y!_L%ZK;Z3^T]X4:XD6-9VD@0L<99EX'Z5^SU>SQ"W'&1DNR_-GE9(E+"R MB^[_ "1^!&KZ;K'P@^),]I*CVNL:#?X <8(:-\J?H< _0U^UGP"^,NE_'/X: M:5XFTV9'F>-8[RW!&^"<#YU8#WY'L:\+_;9_8LC^-MJ_BSPC!#;^-;=,2PD[ M$U",= 3T$@[$]>AK\_/AA\6_B-^R3X_N1:PW.DWJ,(]0T74XF6*=1V=#C\&7 MGT->G6C3SW#1G3=JL>G]='T9P4I5,GKN-17IRZG[@CI2U\^_\ !,S_ )-MC_["MS_[)7QE^W=^T5X3_:$\7^'[KPF+Y[73+:2"2:]@ M$7F%F!!09)QQW K[._X)F?\ )ML?_85N?_9*^EQE.=')J<*BLT]OFSP,+.-3 M-9S@[IK_ "/!/^"L/_([^!O^O"X_]#2O>/\ @F3_ ,FW#_L+7/\ )*^>_P#@ MJSJMO5<_=#.-N?K@UB_LF?MV:%^SU\-AX3U?POJ.J'[9 M+/5 M;R."35;UUFNEC)^8J@&Q,#/.6KYV.4XQWYHQ[LLSPJLHSNWT1^A5?E! M\$/^4BMU_P!AV^_]GK]504L+(%Y"R0Q_-)(<>M27" MQV%UXANHTE8_*0[LJG)['/ZUVY/%RI8FW\IQYHTJE"_\Q^OXZ5XY^T]^SUI/ M[17P[N=%NE2WUFW!FTO4-N6@FQQG_9;H1_7%>QCH*6OGJ56=&:J4W9H]RI3C M5@X35TS\,? ?C7QA^RE\9VN4C>QUG1KAK:_L'/[N>/(WQMCJK#!!^A%=]^UG M\3='^,'Q\\,^+-#E\RRO]-L6,>_^TJ_1*W_ -1'_NC^5?G+_P %9=6MI-7^'VFHZF[BBNYG7NJL M8P/S(/Y5\9DG^_P^?Y,^KS>WU.?R_,],_P""5_\ R0G7O^P[)_Z)BK[1'2OB M3_@E7J5O-\'/$]@D@-S;ZQYLD?=5>)0I_$HWY5U/[=?[6:_ WPO_ ,(QX([''/V" Y!E(_OGD*/4$GI@UC<-4Q.9U*--:M_P!,C"5X8? 0JS>B M1XS_ ,%&/VK'N)[CX4^%+U3".->NH'SN/:U!';H7_!<_>%=[_P $[OV73\/O M#8^(GB:RV>(]7A_XEL$R_/:6K#[_ #T:0'\%Q_>(KYR_X)__ +/%I\<_B-J? MBGQ0?[1T;0)$GE@F.XWMU(2R!\]5&UF;U.!T)K]:% 50 , # %=F8UH8&BLN MP_\ V\^_E_7DCEP%*6,JO'5O^W5V/RG_ ."BW[-J_#7QQ'X\T&S,?A[Q!,?M M<4:_N[:]ZGZ"098?[0?U%>S?\$V/VEW\3:,WPN\17H?4M.C\S1)93\\UN,EX M<]S'P5'7;N'1*^ROB3\/=%^*G@O5?"_B"T%YIFH1&.1/XD/574]F4@$'L0*_ M%7XD^!?%?[+GQHGTW[5+8ZQHURMUI^I0\>=%G,4RGH<@C]TAT%+7C/[+/[06G_M%?#"TUR/R M[?6[7;:ZM8H?]3< ?> Z['^\OXCJIKV4=!7QM6E.C-TYJS6A]73J1JP4X.Z8 MM%%%9&@5\,?&+P6_@?Q]J-F%VV2?M"_#P^-/" M/VVSA\S5=,S+&%^\\?\ &H]3QD?3WKX[BC+'F&!R$\-C_9;GZ9K[ M7EBM-=TQXY4CN[*ZC(93ADD1A^H(-?G?7T+^SI\918F#PGK4V("=NGW4AP$/ M_/$D]O[I_#TKXGA/.HX:3R_$OW)[-[)OH_)_GZGW7%^23Q,5F.&7OP7O)=4M MFO-?EZ'"_&/X-WGPWU%[NU1[KP]<.1#/U,)/2.3^A[_6O0OV??C;&J6OA;79 MRKC$=C=R'@CM$Q[$= ?PKZ$U32[36M/GLKZ".ZM9E*20R#*L#V(KYF^)O[,E M]I+RZAX4W7]G]YM/+8;BYM8CY8N M'0BY@'3#@\N!Z]?K7TEX>\3Z7XILEO-)OH+^W;^.%@<>Q'4'V-?:Y9G.$S2% MZ4K26\7HU\NOJCXG-,FQ>53M6C>+VDM4_GT]&>7?%C]D/X5_&G4;C4_$?AI/ M[9G #ZI83O;W#8& 6*$!L ?,#TKP;6?^"4?@"ZE+:9XP\1Z>IZ).()\?CL4 MU]PT5];1S#%T%RTZC2^_\SY6I@L-6?-.";/AC2/^"4'@:WN0^I^,_$%]"#DQ M0)!!D>A8HQ_*OHWX2?LO?#3X(E)O"_AJWAU +@ZE=L;BZ/KB1\E<^BX'M7K5 M%%;,,5B(\M2HVNW_ P4L%AZ+YJ<$F%%%%>>=H5YM\4_V>?A[\9X@/%WABSU M.Y5=J7J@PW*#T$J$-CVSCVKTFBKA4G3ES0=GY$3A&HN6:NCXLUK_ ()7_#.^ MNFET_P 0>)=+C8Y\GSH9E7V!://YDUJ>$_\ @F%\)-!G2?4[G7O$14@F&[NU MBB/U$2*W_CU?7]%>B\TQKCR^U9PK+L(GS>S1S7@;X>^&_AMHJ:1X8T6ST/3U MY$-G$$!/]YCU8^YYKI:**\R4G)\TG=G?&*BK):%/4+-=0LI[9I985E0H7@D* M2+GNK#D'W!KYYO/^">_P1U&[FN[KPW?7-S,YDDEDUBZ+.QY))\SFOI*BMJ6( MK4+^RFXW[.QE4H4JUO:13MW1\S?\.Z?@3_T*EU_X-[K_ ..4?\.Z?@3_ -"I M=?\ @WNO_CE?3-%=']H8O_G[+[V8?4<-_P ^X_U6OBQ\&O#/QJT2+2/%<-W>:7&_F?98+V6W1V'0 MN(V7=CMFN]HKF=:JZGM7)\W?J=*HTU#V:BN7MT/F[3?^"?GP3TJ^M[VR\.WU MI>6\@EAGAUB[5XW!R"").N:^B;*V%E:10!Y)1&H4/,Q=VQW)/)/N:L44ZM>K M7M[6;E;N[BIT:='^'%+T05Q?Q$^#_@SXL6'V3Q;X9'_N2##+ M^!%=I16492@U*+LS248S7+)71\?^)?\ @F!\(]9D>33KKQ!H!8Y$5K>I+&OX M2HQ_\>KGH/\ @E'\/EDS-XO\2R1Y^ZAMU/YF,U]PT5Z<>\MPC=W M31\J^'?^":_P5T-T>[T_5M>9><:CJ+!2?<1"/-?0/@'X;^&OA=H?]C^%-'M] M$TS>9/LUL" 6/5B222>*ZFBN2MBL1B%:K-OYG32PU&B[TX)?(\#\;_L2_"CX MC^)+S7_$FD:CJVK739DN9M7NLX[ /A0.P' K"_X=T_ G_H5+K_P;W7_ ,/PO>1R*VY676+L%3Z@^97TQ165+$UJ"Y:4W%>3L:5,/2K-.I%-^:,_1 M=)BT+2;33[>2>:"VC6)'N93+(5'3<[9+''<\UH445SMW=V;I6T"OECX\_L#^ M$/BWXJ_X2O1KQ_"GB5IEGN'AB$EM=L""2\>1ACC[RD>X-?4]%=%#$5<-+GHR MLS&M0IUX\M170R)=D2+UP *\0^)'[&_PP^+7BJY\1>*])OM6U690AE?5;E B M#HJJK@*!DG '4U[E14TZU2B^:G)I^6A52E"JN6HDUYGCOPH_97^'OP2UR;5? M!UA?Z1^ M?S)KB35;@=L !\* .!7O]%:K%XA3=15'S/2]]3)X6@X+^TYI89QSC?&[%3C/!QD5[$O %+16-2K.M+GJ. M[\S:G3A27+35D%?+7[>?[,LGQU^'B:QH<(?Q=X?226UC4S/Q+_ &4OVA[_ /9O^*,.JR)+ M+H-YBUUBQ499X<\.H/\ &AY ^HXR:_:30-?T_P 5:)8:QI-U'?:9?0)<6US" MV5DC895@?H17Y>_\%&OV:E^&_C5/'VA6VSP]XAF87D42G;;7A^8GV63YF_W@ MWJ*[#_@FE^TN^FZBWPI\0WH-E=%I]#DE;_5RYS);Y/9^64?W@P_B%?7YGAZ> M8X98_#K5+5>7^:_(^8R^O+ XAX*MM?3^O,_22EI%^Z*6OB#ZX**** /F']H/ MX*G39KCQ3H4'^B.=][:QK_JF[R*!V/?TZ].GS_7Z-NBRH58!E(P0>017S[\5 M/V:8;\3ZKX4"P7)R[Z82%C<]_+/\)]CQ]*_)^(>%YRG+&8"-[ZRC^J_R^X_6 M^'.*X0A'!YA*UM%)_E+_ #^\YGX0_M$3^'A;Z/XF=[K35PD5_P M) .P<=74 M>O4>]?3NEZK9ZU91WEA)P,E"3UM]F7GIM\M/(^X_$/A#1/%#_P($_K7$^&OVMB-L?B#1.., MW&G/G\=C'_V:O2-)_:#\":JBDZVMFY_@O8VB(_$C'ZU]TL=D&;-3G*'-_>]V M7WZ/[F?!2P'$&4)PA&?+_=]Z/W*Z^]'1^$_#VK: KIJ'B.ZUV$@",74$:.GJ M2R@;OQKIZY:+XG^$9DW+XFTDCU^V1C^9JG?_ !D\$Z:A,WB?3B1VAE\T_DN3 M7OT\5@L/34555EWE?\6SY^>%QN)J.3HRYGVA;\$D=K17BVK?M0>'8Y1;:)8W M^NWCG;&L41C1CV S\Q_!:ZGP ](^)W@W M5O#&O6PN]+U*!H)8^,C/*NI[,I (/8@&OS1U[_@F1\5O#_B:23PSJVC:A903 M"6ROS=O;3C:%H=,^)VFZ:NL6<:H-6TV\$J7N.-SIM4H_]NX4445F:!1110!SWBCP/H?C2U^SZQIT-XH&%=AB1/ M]UA@C\Z\6\3_ +)<$A:30-::#/(M[Y-P_P"^UY_\=-?15%>+CLFP.8ZXBFF^ M^S^]'M8#.,LTKKE@U!>2U^]W.3\(?#3P[X&BQI.FQPRD8:YD^>5O MJQY_ 5UE%%?8T:-/#P5.E%12Z)6/C*U:KB)NI6DY2?5N["BBBMC$**** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** C "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D! end GRAPHIC 4 sngx-20230414xex99d1002.jpg GRAPHIC begin 644 sngx-20230414xex99d1002.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" ", 30# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4**** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0 M]*3)YH =13=U.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH *,UC^*/%^C>"M+;4=X;:N3T%5_"'C[P_X]M)KGP_JUOJUO M"XCDDMF)"MC.#6GLY\O/RNW?H8>WI*I['F7-VOK]VYT%%%-D=8D9V.U5&23V M%9FX[-%<-I/QO\"Z]KD6C:?XGL+K4Y9#$EM'(2[,.H''7BNX!S6DZE>!?M-? M&[Q+\(+[P\-&M;1[2\,AGEN8S)NV[?D&",9!)SSTKWT\UY;^T+X"A\<>!B&B M$EQ83+<1G'([,/R)KTLNE1CBH?6(WAL_F>+G$,34P-182?+46J?HSO\ PYK, M/B'0=/U2W.8;R!)U^C '%:0:O.O@2\EOX!MM-ESOL&,*Y_N=5_F1^%8^HKJ> MJ?M":9Y-Y9##*1&Q()^=>AYVUYN,:PU5P2OK9'32Q,G0IU)*[E9? M-[GKCR*BEF("@9)->9>"OVA?#/CSQYJ/A;3!=-=VF[;<.@\F;:<-M(.>/<KTBO/OZ'E8G'8N694L'A8^[O-OHNB7F?0P. M:6FCK3J\8^F"BBB@ HHHH **** "BBB@ HHHH **** "BBCK0!\S?MRZJ(/ MNC6.PDW%\&W ]-JDUJ_L4:.+'X57%XT;H]Y?.V6/#*H !'ZUYO\ MV:LDGB# MPUIZE]\4$LS _=Y( _&O^O?'.WNWB600+/=-D_<)Z$?B:_0$=!7Q)^ MQ%IA'B?Q%JOD-(UI8A$8' ))SCZG%>Q?"O\ :D@^(_CY_#$GA^72Y@) LQN! M("4.""-HQ7UW$-"MB<;4=*-U3BK^2/SW@_%X? Y=2C7E:5:;V/>J:U9^O MZW;>'=&O=3NW$=M:Q--(Q] ,UXO\(?VG9/BYXP;1K+PO+:V\:-++>-=!@BC@ M$C;U/IFODZ6$K5Z4ZT(^['=]C] Q&8X;"UJ>'JSM.>R[GEG[;.K--XTT:P#* M4MK,R$#[P+,>OX 5?T[]CF+7?!=IJ=GXBF74+FV6989X%\K)&=N1S^-<-^TW MJ*ZK\<+U)#'"D!A@+L?EP ,EJ^B=0_:;\ ^$_#<,5MJJZK>06ZJEM8QL0S!< M8W$ 9KXR,UEL?#0A@L5C\74QS5D[*[M]QX#^SW\0]8^&OQ+@\,W M%]5^*7QDAUL02164%Z=0NK M@#*(J+HFB7VH.N]+6!YBI.,[5)QGMG%=V5N7L9A[ M7#$/VOM,UX:I/J6ARZ18V%OYS3_:!*7$:M^T_'HWQ4/@VZ\.R18OTL_MKW2@88C$FTCIR#UKW0 MG S733K0JWY'>VYZ%#%T<2Y*E*_*[/U'TR618E9F8*JC)). !7@MM^U-'K7Q M,'A+1/#LFI%[PVB7WVH*C!3\\F-I^488_A65\;/VH(_"&N^(/!\6A_:ID@\@ M79N@%S)'GE,9XW=,]JYY8R@H.?-HM/F<%3.,'"E*KSZ)VZ[]CV3PW\5?"7B_ M4VT_1=?L]2O54N8+=B6"CJ>E=1<0)=V\D4@W(ZE2/4&OSM^"7Q6M_A!XBN=5 MFTQM4EDMOL\:BX$6P$@DG(.>@K[3^#'Q8_X6[X;NM9_LHZ3;PW!@0-.)!)A0 M2<@#&,XK'!8Z.(6NDCCRG.:>8QY9M*;OHK['4^'_ ZF@F7RR-L@ *CVZ4EE MX=2W\0WFJLH,LJ[ 1ZE8?A#]M-IM8BM?$V@)86LA -S:.Q://=D8K5JP48=-O(]94E!2E2WEU&^"/$=UXL\.6FIW>FR:3+/DBVE;<0N M>#G ZUT-*V0_PX4J M,'\)_A1HD>JZU/8M;R2B%5MYF=BQ M]B!7Z0&OE;]NS5Q%H/AS3%EPTMR\SQ8ZA5X.?K7-E>?8W&8RG0GRV;UT.S/> M%74D_85TI8_#'B*_)?=-/G1O7H36^$K?6,WQ5![34E]QS8_#/"<.X'$K>DXR^_<]._;0^)*Z M+X5M?"]I-BZU(^9/L/*PCU^IKHOV2/AI_P (3\/5U:[BV:GJY$[@CE(_X%_+ MG\:^:_#<6H?M'_'*UENU';IT4I!:VS$* M@Z*JGI^5>3FK668&GEZ^)^]/]$>YDV[9U9+EN%S"E5KXB M%W*3U/A/PQX\\9_LT>,FT+5!]HTI'!FLF.Z-XR?]9$W4'O[]#7U!\8_%%M4P.,B3 !_6O ?VT]5TV\\7Z/:V[H]_:VS?:2F"5!.54^_4 MX]ZVOB+>3:1^R/X9L[A9%FNO(0#&W:!EN1]*5.I*A[:BG>,5IY>1.'KRP7US M!QES0A%M>7D>8?L\?"#_ (6KXHD%]YJZ#8A9+K82OG-_#'GWYSWQ]:^T_#?P MG\)>$=574M&T&TTZ^6#[/YT"E3L^G3/'7K[UY5^QAI?V;X:WMYN)-U?N=I7& M-H"]>_2OH+E^&A"A&5M7J>SD&7T:.#IU7%.4M;O\#X>_:UTMO#7QE@U2 M)47[5;07:D G+H=I)_[X%?0'QL^*R^$_@P-4M)=NH:Q;I!9,.)EGQVVKD M_7% ZGXFUCXLS^#?#$*.6LH(]. MMHR^[?(Q^:0_ACZ!:\ZK6>%K5H1WE:WS/G\5BY9;B\51I_%4MR^K_P"'/+3=(^%MY.EE;1:A?W44'VA; M=?,;GOS5W5:2PN!<>MOQ9[>)PTYH?L>> M"].O/A_J.I7]A9WKW%^R1F>!790B@8R0>YKKOVD/%$?PS^%-U#H\46G7&HRB MUB%L@CV[OOL ,<[0>?I6U^S=I(T?X+^&8SN#3P-P'O6U^T=\6O WQ0T6P;0X;@:S;3@^= M-:F+,1!W GOSCBO4_P!FOX>>#/%?PGTV\OM TO4K\22QSS3VZN^X.< DCT(K MT]O@SX!12S>$=& R2;1./TKFHX6M/#*FI1LUV/.PN68RMET:,)P4)*^SOKK MOW.1_9-UFXUCX062SL6^R3R6Z$G)V@@C^=>I:[I3ZK:F)'VL?4D"HO"ND:)H M^D)'X?M;.UTYV+JMBH$;'."1CCM^E:L[,L3%!N<#@'O7O8=2HTXIN[2/L\+1 M='#0HU'=I)7[GD>J_L\V7B&1CJ&IRK&W5+6, _\ ?1S_ "KJ/AK\'_#OPJAN MTT*"=9+LAIYKB8R,Y'3V'T I+_Q7XFLM3M[:/PV;J"20*\Z.0%7/7N*[93DU MVO,*]>#I.;Y>VR,:6"PD:OMH4USKK;4?10.E%+=&31M U'5K*WM6)EL[5I KD]"0/TK MZZ(S32OJ,UG@,;++ZZQ$(IM=S?-\LAF^$EA*DG%.VJWT.(^"GAZX\+_"_P / M:;=VYM;N*V'G1,NTJQY((]:\ _;M>P,?AI?,7^T@TGR9Y$?KCZU]97$Z6L,D MLC!(T4LS'H !R:^!-?GNOVC_ -H,6L#%].,_DH>R6R'YF_'^M>[D2E5QTL=4 M=HPO)_/H?)\4N&'RNGE=).**UC+R,Q& !S70:3IL&D:;;65K&(K> MWC6.-!T"@8%6F&:^)9+03>=<3GKAVY 'KR379_M:^&=9US0/#FD>'M%U#4(H9'=TL+?#5YX4^ M$FA6&H026M[L:66&5"CQEF+;6!Z$9Q7HYZ4#I0QP*[:<%3@H+H>U0I1P]*-* M.T5;[CQ/]KL6+?!Z[%W*D<_VJ$VH*Y+2 G@>GR[N?3->6?L9_#?[?JU]XQO( MLQ6>;6RW#@R$?O''T!"CZFL3]J3QK<_$/XFVGA32R9X-.D%K'&G/F73D!C^' M"_@:^LOAMX,@\ >"M*T. #_180)''\+"*Q6-=1;0T^9\?2I0S+. M)8A+W:2MZO\ X!U X %?-W[8GPZUGQ5INC:QI-G+J"Z?YJ7$$"%I%1L'> .2 M!MYQZU](BD*@UZU>C'$4W3EU/J<;A(8[#RP\W9,^&?#WQB^+G]@:;X6T?3KM M#!&+>*>/37,Y0# &YA@8'>OJKQK\-H_B%\,QX+R0 NLZJ,.??/ M7ZFN[VX__71D=,C/:L*.%=.+C.3E=6U.#"98Z%.5*O5=125M=DCX1T*?XH?L MY:[=VMOI4\MK*QW(;9[BUN,='4KT/X@^M;5]XO\ C-\=)/[*M=/N=,T]\+-] MG@>TA [[Y'Y(]@?PK[0N9H[:%I)&V(.IS3HV65%=3E2,CZ5S1R]Q7(JCY>QY M\,B=->QCB)*G_+^ES(\$Z$?"_A+2-);R_,L[9(7\D84L!R1[9S4^K^(+;1L& M?=M[[>H_"K.H23+9RM; /*HR!GJ?2N6T?4]*^(=C<6UQ&/MEN=DL?W77W%>M M"5.$HPF?2/\ =Q5.&_0Z'2?$6FZZA-C=Q7)'WD5OF7ZCJ*T1@BOFSXG_ !\ M7V\_]H^"M4\RY5LHCS?9YD^C]#^->Y_#^SUNP\&Z3;^(IQ=:W' HNI5.=S_4 M 9^M>EB,/1ITXU:512OTZHX,+C*]6O*A6HN-E?FZ/T\SHZ***\\]@**** "B MBB@ HHHH **** "BC-&: "BBB@ HHHH *#TH-% ')_$[PUJWB_P7J.CZ-J,6 MEWEXGE?:IE9@J'[V,7)8]@3^)KZ&I,"EK&E1A0CRP1QX7 M!T<%!PHJR;O\PHHHS6YVB,<"O-=4\;_;/'BZ/:29:-UA.T_Q'EORKTB3+(0I MP?6O#_A)\)/%'AWX@ZQK7B2>VGAWR&U>&0L9BYSO(_AP"1CUKOPL:7+4G4>J M6B[L\O&3K*I2ITHMIO5]EYG<_&'5Y-"\"7=U'NRCQJ2H)X+ 5T6B&2[\,6+- MNCDDM4)SP02M:S1JZ[64,/0C(I<#&.U>4HM5'.YW*#YW*_0\N\+^/A!XRET/ M4'\N21S&N\_\M!T_.N\T[PQIFEZK>:E:VB0WMV!YTRYR^/T%>;_$3X&W'C#Q MSIFNV&L#2HXW1KJ,1DN^TY!0YP#VYKUT$5Z>*5"?).GO;5=F<6$5?FG"O'2+ M]U]T+11FD# ]ZXCTQ:*3 M;_$W5[[6-I[KB^NX6VO;V:'YRI[,Q^4'ZUSGA_X@Z-X>^)'B MZ36O$'V'3[9K;2[&"\N#M)5,N0O))R1EO?K6YX+']H?%KX@:M)\ZV:6NFP29 MQM54,DB_FP.:\P31M,;X)^-?%=Y86UUJ6M7EQY4UR/,D4&79&JGJ"#G&/:K\ MF1KN?1=GXFTS4-4GTZWOH9[Z&)9I($;+*C?=;Z&LR?XF^%;7=YVO64065X"7 MDP!(@RRY]1WKQXZTOPY\0>(KDY>>S\*V,$0Q@R3$[4&/4L14?AKX>VDWCOPA MX?U2&*\_LG3)-4O4=,A[F5@?G_'_ -!I60[GN6A>,M$\3:0VJ:7JEM>Z>N=U MQ')\BXZY)Z?C5;P_\1/#?BIKL:1K5GJ!M,F<0R9* =2?;W'%?-^O3SVFH^,M M'TFSEGM-6UZ&U_L^P*AI J;Y57.%&1QS[UT&IRZC8ZKJ?B$>#+OP?IEEH,UH M!=+%MD<]37CFH^ --\+_#/PE80V MT7]L:[>6JW-U,I,S#(.875P^EVY.ZC!#X0\1:^D%T+F#PSX;^R1RW(RS-)GAB M.AY[5!=^!--T?P;\--.MK)4U6^U"&XDN8HMLS<;G)8\CZ46"Y]$:KK-EH6GS M7VHW45E:0C=)-,VU5'U-4O#WC/1/%>FO?Z1JEK?V:9#S0R9"8Z[O3\:Y3XW> M'M2U[PE"^F6RZC+874=X^GN<"Z1#DI]>]>::WJ.@:[X8^V>&7EL+KQ9J4%AJ M-J[;#;E?]8FP#@X&#ZTDD%V>W^'/B#X<\775S;:-K-IJ-Q;'$L<$F67\/3W% M&+:2SBGUG5]1MG:[V?O7ED; M'[S4_%TLBW'BW M1[.#399M1@CCU%UCLV9O]>S#("^N17SWXSN))H/B3<1B3,]Q9^'[=C)M"C*@ MCZ$+2^2S MF\16$=T]P;01&7YO-!P5_,@>E6](\?\ ASQ'K%UI&FZS9WVH6PS-;P2;F09P M?8_A7SF_A6QOO@I:WTMFK:UXIUQ&$WD_O 'F/"$\@; 2/K7I&D^&=+LOCY96 MVEV26<.C^'PLH@01@O(Y"YQ][Y<_B*&D"9T/P4U&ZET+6-.O;B2XN-*U:ZM" M9G+R*@?<@9CR?E85T?B'XA^&_"E]:V6KZU9Z==W1 BAN)0K-DX!]A[G KE/@ MNPNF\:ZFO$-[X@N713U 0*AS^*FN L]*LO$7PG^(OC?6+:*>^U9;PP37*J3% M#&"D*I_=Y4=.^/:BVH7T/7/%]M#K/B'PM9#Q"VE3QW1U!;&$?/?I$.4SD809 M!/7(/2EM_BQX/N+VQLXO$>GR75\Q2WB67YI""5Q[<@CG&:\>LM6F@URWU.Z+ M2'PQX#%P2KX/FRID%1Z[5P<^U4KKP+IVC?"/X<6 M+5-=U?4[*62\*AIBS'S M&8,.2,8&.P-.P7/1G^,^G3_%^V\-V^LV)TW[-(DP"YC:O::E):-MG6WDW%#[^WOTIFE_$3PUK>N3 MZ-8:W97>J0YWVL4H+C'7ZX[XKPOQ?>+X6\0?$N]T&TCLA;:?9:1#%:(%)EE; MA@!@#@X]>*FTW2=135?!(M_ &I>'+/0':6ZU"Z\GYU\LAB2C9.3S2L.Y[#=_ M%GP?97:6T_B/3XIVG-L(WEP?,'5?\\5S?C#XR6.A_$30?#\6K:?#%([?V@TQ M+-'Q\B#'0L3P:\ME\/V(^ &I:W/81S:MKU^9$N)8@'7?-A"">0,<\5W?ASPS MI^K_ !JU#[1I]M*-'TJ")R;=2IG;&221RP X-%D*[.T^*'C&\\+:/:PZ3''+ MKFI7"VEDDO*AVZN1W '-9'P\UOQ+:>-M8\+>(]3M];DMK6*\COHK<0$;S@H5 M'! /0U'XH5M7^.'A2R*YAL+2>^.YL MPJD#U&:9X"D?6OC#XXU3=NAM4@TY" M%P"0-Q_$9HZ#&^--5\<:MKNKP:!=IXR8SL7=P$ ')'-8U M]\0O%GBO1O ]IX>O+72]*-:_X0/PN M UY.F=3U#JEC >HX_C(Z"J>J_ Z6YUNSDCUFZTO1--TO[);+ITS1W!;J2S8X M&>>.M->8$MS>>/?#=I8Z1J/B*RU#7=:N_L]K=PV.V.TC"Y=]N/F;T!XJ;0OB M1J5EX&O9;^XAUK7(;Z33+1X(_+^UR@X4E1P/4XXXKGO T'BSQ=X(T/5K/4;8 MZKI%S54"@OWP!T Z5I5ROPS\6S>-O M!UEJMS"D%S)N258C\FY6*DK['%=54%A1110 4AYXI:#S0!Y!X?M[M?%OQ9T: MR2,WEQ>'=.@UR?6([2-=3GA6WDN1GQIW%8\0\3^%AXJ_:*LX%D$EC!917NH1=>8W)B5OJQ!Q[53^U> M-;OXL^,=:\*65GJ4< BTIX;Z7RBI"[MRGN 3G'?->J^!_AOIG@-;Y[2>]OKR M^<27%[J,_G3R$# !8CH*O>%/!EAX0_M(V1FD?4+I[N>2=]S%V[=.@["JN38\ MNF^$GB'P]X8T*[TI[74_$^GZ@^J74<[;(KJ63.]0W; /&:NZOX)\<^+O!^JQ M:O=V\=[J=S"1ID4O[BS@5@64/C+,1UKV*BIN58X+Q-X)OM9\7>#[F)XQH^D% MY)5+?O"^S:F..1US7%Z7X)^(>@W-]X?TDV.G:'(=4T_P 7H)H6N-9OH-K/*/\ CU3&<_+PW%=9J_@B^U'Q MYX5OU$;:1H\+YWRD.9"H"D*!V'>N^HHN%CB/B!;^+[>^TS4O"QBODMBRW6DS MS");@'H0Y'!%>=S?!_Q/_8O]LA+!O%0U@ZP+!)"L'(QY0?'7 Z^M>]T47"QX MF_PH\1>-=/\ %.J>)C:66NZM:"TM+6W??':1J=P!;N21R14&F^!_'OB/6?!L MWB*RTNRTK0G+-:QW!D>5E3:LAP,#:G\(_$\/@P-:6]A66/"[>/FPV3VJEKQO/ MAWJ_CGQ;>)%-=ZLT%CHUO')OED8)M1,8XRQW8&<G'O77:_X%O=2\8> M"+F$PQZ-H0EDD1?E;S/+"1A1C[N,_3BN^HHNPL>#1?#?QBWA/QYX;_L^QA35 MM0ENK;4#=\RI+*"0P R-J#O]*[F\\"WEQX^\(WZ1VR:-H5C+$!N.\RLJJH"X MP ,YKT#%%%PLCQ?4?A'KFH>%/%\1EM(]8U35QJ5LN2T>V,J8U8]1D+SZ9J_ M!HWQ$\2Z7KESK)M=)N)]/>SLM(M+@-&)".9G?!P?0#M7K-%%PL>5:E\+]0N? M"W@/0H4MA:Z1<037WF2$Y$8R0HQ\V6SUQ5KP5X9\1Z!\2O%5W>6D$VDZI(L\ M5^)\R *N%CV=L<\UZ711<+'F'Q!\.>*K7QG8>*/"UI9ZG.E>O8HQ1<+'B M'@/PU\3/!<5S$NC^';F6]NFN+N]EOI3+(2>I 7' X K3\1:-\1K'Q%K T1;3 M4-/UB-46:ZNV4: --\)Z3<*D3XCO[XL5 M?RSS(4'.6;D>P-5?%OA#7M+U73+KPG96]Q'#I[Z8()[CREM@W24<'=CN.IKU M"BBX6,3P7X<3PEX7T[24<2&VB"O(!C>W5C^))K;HHI#"BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** =** "BBB@ HHHH **** "BBB@ HHHH **** /_]D! end EX-101.SCH 5 sngx-20230414.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 6 sngx-20230414_def.xml EX-101.DEF EX-101.LAB 7 sngx-20230414_lab.xml EX-101.LAB EX-101.PRE 8 sngx-20230414_pre.xml EX-101.PRE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
Apr. 14, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Apr. 14, 2023
Securities Act File Number 001-14778
Entity Registrant Name Soligenix, Inc.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 41-1505029
Entity Address, Address Line One 29 Emmons Drive
Entity Address, Address Line Two Suite B-10
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code 609
Local Phone Number 538-8200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $.001 per share
Trading Symbol SNGX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0000812796
Amendment Flag false
XML 10 R2.htm IDEA: XBRL DOCUMENT v3.23.1
N-2
Apr. 14, 2023
Cover [Abstract]  
Entity Central Index Key 0000812796
Amendment Flag false
Securities Act File Number 001-14778
Document Type 8-K
Entity Registrant Name Soligenix, Inc.
Entity Address, Address Line One 29 Emmons Drive
Entity Address, Address Line Two Suite B-10
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08540
City Area Code 609
Local Phone Number 538-8200
Entity Emerging Growth Company false
XML 11 sngx-20230414x8k_htm.xml IDEA: XBRL DOCUMENT 0000812796 2023-04-14 2023-04-14 0000812796 false DE 8-K 2023-04-14 001-14778 Soligenix, Inc. 41-1505029 29 Emmons Drive Suite B-10 Princeton NJ 08540 609 538-8200 false false false false Common Stock, par value $.001 per share SNGX NASDAQ false EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ")$CE8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " B1(Y6'8R1*.X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>.FTG#E&7"X@32$A, G&+'&^+:)HH,6KW]K1EZX3@ 3C&_O/Y ML^06H\*0Z#F%2(D=Y9O1=WU6&+?BR!P50,8C>9/+*=%/S7U(WO#T3 >(!C_, M@:"6\A8\L;&&#IX8 M3V/7PA4PPYB2S]\%LBMQJ?Z)73H@SLDQNS4U#$,Y-$MNVJ&"MZ?'EV7=PO69 M38\T_621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M ")$CE9&IV1Y:P0 #<1 8 >&PO=V]R:W-H965T&UL MG9AM<^(V$,>_BL;M=-J9)'X(3TF!&4*2:WIW.1IHK]-.7PA[ ) M5Q9*9]SBH5[Z)M? DW)0EOI1$'3\C OI#?OEN8D>]E5A4R%AHIDILHSK[0VD M:CWP0N_EQ)-8KJP[X0_[.5_"%.SO^43CD5^I)"(#:8223,-BX(W"ZYNH[0:4 M=_PA8&T.]IE[E;E2G]S!0S+P D<$*<3627#Y&-;=3OFHY M&N&$=%F96HU7!8ZSPUL5%QADR[A,V)VTPF[9@]QE&Z/6]RT^Q-WJQWO!FYU@ M=$1PE.L+%K;.6!1$EU\.]Y&M HPJP*C4NSRB-U;/H-G?H[FQ&E/X3Q/13J'5 MK.#J^MKD/(:!AX5K0#^#-_SAN[ 3_$SP759\EY1Z'<#9-HXC9IQ*7%;^\(PEY%V'L-X8QO MV$."92<6(BXQBZR3$G#;C4V$8(Q#&KC#?X_Y6RM&JV7EIP6 FODYCP,*,*#UA#^)\*Q M.\(*G*EUT(QZ+5;9$[K1A'2_E[F<(3KM^,HM$ GH*9H6+>% MD/;R=RK&F$Q62E+]X(1(^[)WWL,%*$54-X20=O*/V*8L2 Q,EA5R[VBFD8H6 M6O#4D!Y1=X*0=FO77&)LGG+)WF-Y:\'31AY:Y21/[?LA;=,3#>L6 M$-&>/=,\<=4WW69SU5A[)P2FCV_^I$@./@-H;WX)&+O;Q"LNEW!TO79"Z'$T MO1W]1C'51A^]RNCO,M!+%Z4WJ&!7SD!R+IM32PN>++?:YR/:IO=H8YP*&GWV M 6?!AKV%9BA:*L"_7AAUKSH466W\$>W9(YR>23E%[U.^;.2A!8X&R3_X#'8_ M*;SG+BV&I;! H>"BB[IZ]Y6^.[ J+[^,Y\KB=W:YNP*.?N%NP.L+I>S+@?O8 MKGXK&?X+4$L#!!0 ( ")$CE:KU^S3,@, 0+ 8 >&PO=V]R:W-H M965T&ULG99K;]HP%(;_BI5)^U2:"[?0 1*EW=:UZU#I-FG3 M/ICD %83.[--:?_]C@,-3 NG[9 @/HG?UX\O.9S^6ND[LP2P["'/I!EX2VN+ M$]\WR1)R;HY5 1*?S)7.N<50+WQ3:.!I*ZN48YU5*-<$*Z79E:C4\%ZNSPNA'U?8M&+O23K>AT(XH.B$:%/F9AZXA% M0=3\6^[C^!5$5$%$I5_S@-]8W8-F/T M3@/Z'KSAVS=A)WA'\#4KOB;E/CR75MA'-@:)?!F[D"D\L$MXK..DG0+\Q&'4 M[74(K%:%U2+-1OAVI/BU['W&%W4PM'[.,P,$1[OB:),^4TA66E@!AHT2A!$9 ML.M5/@-=QT1[!4'8"%O=;DQP=2JN#NEUII)5N3RWCP74H=#RN'%)0'0KB.Y+ MSLX-+(0[W4ASS?-:&MIGJC*Q "D>CO#\)<<$65R1Q2\A&Z4IOC'FZ*G!KK ? M^R)K&6G'J,?.\UQ)P\XTYEJ"L5UY_8E" MVV7\D$S8_Z!-E+&86G^(@HU56@]&.P9QNT7NZ2[;AW22+O=PA#7.813:H!/T M*)!=?@_I!'VE$ER3R5))*J$^8])NQHT8BS2*:)?I0SH];[?M/ >]$'+!/J"# M7>(ZY067M?^'SQ@>_ _R]VH:5Q]^YFY$PS*8HU%PW$5?O2FY-H%515GFS)3% MHJEL+K%,!>TZX/.Y4O8I<)535?@._P!02P,$% @ (D2.5I^@&_"Q @ MX@P T !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U" M\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.] MDKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"D ML<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#G MN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/ M\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T M\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NFJ:]P MSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL M?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6P MQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y[' MNXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ M(D2.5I>*NQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2 M:5K5N %(MB6/:(7->= MI3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8 M%II%R=.B':5_'T@88XEZ:/0$E#4W*7[76\1 \CK9,V7]^UC&F@4'KI2=K9 M930SJ_G)^4/AW$%\&&U#+ANB=I8DH6S J'#M6K#7A2,H"9UEL =V"*?PW>]+<<2 !6JDSUS&NP8I#%HT M>(8JEZD4H7&G9^?Q["PIO2V]TSJ7DZ&Q T]8_H"WO% O)Y31E MPAI]H#@1^15K/ (/#U5'[A$U@5\J@B?ONA;MOJ=A%\F%C9C#> XASOQ?8G1U MC24L7=D9L#3DZ$'W FUHL U26&4@E^.(4+82#Y8X)+&R Q7/]D[YZ54UN":6 M>Y&AGR$W_*J*PO]/Y/HJNQ"2_2(DBPF.L550HX5JS22!<5YAN?&B/Z*A[.9V MKZK2^9^S5OCA5C5L8?]#B"U!+ P04 " B1(Y6C?][,(D?J!6W9J"FM23&7@^4 MR(;9W@"H:+!7=#(6A_FF,JY7/$=7@U5%IVJ$* BNX/8,F<9[IL@GB[\0356U M!=Y-\>QQX"]@>!G748/(4N3*UO0W\GEXP#>STO?4$L#!!0 ( ")$CE9N MIR2\'@$ %<$ 3 6T-O;G1E;G1?5'EP97-=+GAM;,64ST[#, S&7Z7* M=6HR=N" UEV *^S "X367:/FGV)O=&^/VVZ30*-B*A*71HWM[^?XB[)^.T; MK'/68R$:HOB@%)8-.(TR1/ 60@2F>DC7H@L M/?M\T+M=0?5+-H_W(Z1V\ /5L,R?\5>/+_HW]K'ZQS[>0VC_^JKWJW3:^#-? M#>_)YA-02P$"% ,4 " B1(Y6!T%-8H$ "Q $ M@ $ 9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( ")$CE8=C)$H[@ M "L" 1 " :\ !D;V-0&UL4$L! A0#% @ (D2.5D:G9'EK! -Q$ !@ M ("!#0@ 'AL+W=O&PO"'4 $ ,4" / " =L3 M !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " B1(Y6C?&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"% ,4 " B1(Y6;J XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.soligenix.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995470 - Disclosure - N-2 Sheet http://xbrl.sec.gov/cef/role/N2 N-2 Notes 2 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityIncorporationStateCountryCode - sngx-20230414x8k.htm 9 sngx-20230414x8k.htm sngx-20230414.xsd sngx-20230414_def.xml sngx-20230414_lab.xml sngx-20230414_pre.xml sngx-20230414xex99d1.htm http://xbrl.sec.gov/dei/2022 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sngx-20230414x8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "sngx-20230414_def.xml" ] }, "inline": { "local": [ "sngx-20230414x8k.htm" ] }, "labelLink": { "local": [ "sngx-20230414_lab.xml" ] }, "presentationLink": { "local": [ "sngx-20230414_pre.xml" ] }, "schema": { "local": [ "sngx-20230414.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/2006/xbrldi-2006.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/cef/2022/cef-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022_lab.xsd" ] } }, "elementCount": 199, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sngx", "nsuri": "http://www.soligenix.com/20230414", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "sngx-20230414x8k.htm", "contextRef": "Duration_4_14_2023_To_4_14_2023_MdeXnVNdD0eNF1Hoi7uARQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "sngx-20230414x8k.htm", "contextRef": "Duration_4_14_2023_To_4_14_2023_MdeXnVNdD0eNF1Hoi7uARQ", "decimals": null, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "sngx-20230414x8k.htm", "contextRef": "Duration_4_14_2023_To_4_14_2023_MdeXnVNdD0eNF1Hoi7uARQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityFileNumber", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995470 - Disclosure - N-2", "menuCat": "Notes", "order": "2", "role": "http://xbrl.sec.gov/cef/role/N2", "shortName": "N-2", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 0, "tag": { "cef_AcquiredFundFeesAndExpensesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses, Note [Text Block]" } } }, "localname": "AcquiredFundFeesAndExpensesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AcquiredFundFeesAndExpensesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses [Percent]" } } }, "localname": "AcquiredFundFeesAndExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_AcquiredFundFeesEstimatedNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees Estimated, Note [Text Block]" } } }, "localname": "AcquiredFundFeesEstimatedNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AcquiredFundIncentiveAllocationNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Incentive Allocation, Note [Text Block]" } } }, "localname": "AcquiredFundIncentiveAllocationNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AcquiredFundTotalAnnualExpensesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquired Fund Total Annual Expenses, Note [Text Block]" } } }, "localname": "AcquiredFundTotalAnnualExpensesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AllRisksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Risks:" } } }, "localname": "AllRisksMember", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "domainItemType" }, "cef_AllSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Securities:" } } }, "localname": "AllSecuritiesMember", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "domainItemType" }, "cef_AnnualCoverageReturnRatePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Coverage Return Rate [Percent]" } } }, "localname": "AnnualCoverageReturnRatePercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_AnnualDividendPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment" } } }, "localname": "AnnualDividendPayment", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_AnnualDividendPaymentCurrent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Current" } } }, "localname": "AnnualDividendPaymentCurrent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_AnnualDividendPaymentInitial": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Initial" } } }, "localname": "AnnualDividendPaymentInitial", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_AnnualExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Expenses [Table Text Block]" } } }, "localname": "AnnualExpensesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_AnnualInterestRateCurrentPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Current [Percent]" } } }, "localname": "AnnualInterestRateCurrentPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_AnnualInterestRateInitialPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Initial [Percent]" } } }, "localname": "AnnualInterestRateInitialPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_AnnualInterestRatePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual Interest Rate [Percent]" } } }, "localname": "AnnualInterestRatePercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_BasisOfTransactionFeesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis of Transaction Fees, Note [Text Block]" } } }, "localname": "BasisOfTransactionFeesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_BdcFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BDC File Number" } } }, "localname": "BdcFileNumber", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "cef_BusinessDevelopmentCompanyFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Development Company [Flag]" } } }, "localname": "BusinessDevelopmentCompanyFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Stock, Long-Term Debt, and Other Securities [Abstract]" } } }, "localname": "CapitalStockLongTermDebtAndOtherSecuritiesAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_CapitalStockTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Stock [Table Text Block]" } } }, "localname": "CapitalStockTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_DistributionServicingFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Distribution/Servicing Fees [Percent]" } } }, "localname": "DistributionServicingFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_DistributionsMayReducePrincipalTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Distributions May Reduce Principal [Text Block]" } } }, "localname": "DistributionsMayReducePrincipalTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_DividendAndInterestExpensesOnShortSalesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividend and Interest Expenses on Short Sales [Percent]" } } }, "localname": "DividendAndInterestExpensesOnShortSalesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_DividendExpenseOnPreferredSharesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividend Expenses on Preferred Shares [Percent]" } } }, "localname": "DividendExpenseOnPreferredSharesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_DividendReinvestmentAndCashPurchaseFees": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dividend Reinvestment and Cash Purchase Fees" } } }, "localname": "DividendReinvestmentAndCashPurchaseFees", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_EffectsOfLeveragePurposeTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effects of Leverage, Purpose [Text Block]" } } }, "localname": "EffectsOfLeveragePurposeTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_EffectsOfLeverageTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effects of Leverage [Table Text Block]" } } }, "localname": "EffectsOfLeverageTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_EffectsOfLeverageTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effects of Leverage [Text Block]" } } }, "localname": "EffectsOfLeverageTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_ExpenseExampleTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example [Table Text Block]" } } }, "localname": "ExpenseExampleTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_ExpenseExampleYear01": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example, Year 01" } } }, "localname": "ExpenseExampleYear01", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_ExpenseExampleYears1to10": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 10" } } }, "localname": "ExpenseExampleYears1to10", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_ExpenseExampleYears1to3": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 3" } } }, "localname": "ExpenseExampleYears1to3", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_ExpenseExampleYears1to5": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 5" } } }, "localname": "ExpenseExampleYears1to5", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_FeeTableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fee Table [Abstract]" } } }, "localname": "FeeTableAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_FinancialHighlightsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Highlights [Abstract]" } } }, "localname": "FinancialHighlightsAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_GeneralDescriptionOfRegistrantAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General Description of Registrant [Abstract]" } } }, "localname": "GeneralDescriptionOfRegistrantAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_HighestPriceOrBid": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Highest Price or Bid" } } }, "localname": "HighestPriceOrBid", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_HighestPriceOrBidNav": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Highest Price or Bid, NAV" } } }, "localname": "HighestPriceOrBidNav", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_HighestPriceOrBidPremiumDiscountToNavPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Highest Price or Bid, Premium (Discount) to NAV [Percent]" } } }, "localname": "HighestPriceOrBidPremiumDiscountToNavPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IncentiveAllocationMaximumPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Allocation Maximum [Percent]" } } }, "localname": "IncentiveAllocationMaximumPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IncentiveAllocationMinimumPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Allocation Minimum [Percent]" } } }, "localname": "IncentiveAllocationMinimumPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IncentiveAllocationPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Allocation [Percent]" } } }, "localname": "IncentiveAllocationPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IncentiveFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incentive Fees [Percent]" } } }, "localname": "IncentiveFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_InterestExpensesOnBorrowingsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest Expenses on Borrowings [Percent]" } } }, "localname": "InterestExpensesOnBorrowingsPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_IntervalFundFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interval Fund [Flag]" } } }, "localname": "IntervalFundFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_InvestmentObjectivesAndPracticesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment Objectives and Practices [Text Block]" } } }, "localname": "InvestmentObjectivesAndPracticesTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LatestNav": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Latest NAV" } } }, "localname": "LatestNav", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_LatestPremiumDiscountToNavPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Latest Premium (Discount) to NAV [Percent]" } } }, "localname": "LatestPremiumDiscountToNavPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_LatestSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Latest Share Price" } } }, "localname": "LatestSharePrice", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_LoanServicingFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Servicing Fees [Percent]" } } }, "localname": "LoanServicingFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_LongTermDebtDividendsAndCovenantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Dividends and Covenants [Text Block]" } } }, "localname": "LongTermDebtDividendsAndCovenantsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtIssuanceAndSubstitutionTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Issuance and Substitution [Text Block]" } } }, "localname": "LongTermDebtIssuanceAndSubstitutionTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtPrincipal": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Principal" } } }, "localname": "LongTermDebtPrincipal", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_LongTermDebtRightsLimitedByOtherSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Rights Limited by Other Securities [Text Block]" } } }, "localname": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtStructuringTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Structuring [Text Block]" } } }, "localname": "LongTermDebtStructuringTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt [Table Text Block]" } } }, "localname": "LongTermDebtTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LongTermDebtTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Debt, Title [Text Block]" } } }, "localname": "LongTermDebtTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_LowestPriceOrBid": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid" } } }, "localname": "LowestPriceOrBid", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_LowestPriceOrBidNav": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid, NAV" } } }, "localname": "LowestPriceOrBidNav", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_LowestPriceOrBidPremiumDiscountToNavPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid, Premium (Discount) to NAV [Percent]" } } }, "localname": "LowestPriceOrBidPremiumDiscountToNavPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Management Fee not based on Net Assets, Note [Text Block]" } } }, "localname": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_ManagementFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Management Fees [Percent]" } } }, "localname": "ManagementFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_NetExpenseOverAssetsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Expense over Assets [Percent]" } } }, "localname": "NetExpenseOverAssetsPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_NewCefOrBdcRegistrantFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "New CEF or BDC Registrant [Flag]" } } }, "localname": "NewCefOrBdcRegistrantFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_NoPublicTradingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "No Public Trading [Text Block]" } } }, "localname": "NoPublicTradingTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_NoTradingHistoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "No Trading History [Text Block]" } } }, "localname": "NoTradingHistoryTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherAnnualExpense1Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "order": 1.0, "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Annual Expense 1 [Percent]" } } }, "localname": "OtherAnnualExpense1Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherAnnualExpense2Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "order": 2.0, "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Annual Expense 2 [Percent]" } } }, "localname": "OtherAnnualExpense2Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherAnnualExpense3Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "order": 3.0, "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Annual Expense 3 [Percent]" } } }, "localname": "OtherAnnualExpense3Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherAnnualExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Annual Expenses [Abstract]" } } }, "localname": "OtherAnnualExpensesAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_OtherAnnualExpensesPercent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "label": "Other Annual Expenses [Percent]" } } }, "localname": "OtherAnnualExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherExpensesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Expenses, Note [Text Block]" } } }, "localname": "OtherExpensesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherFeederFundExpensesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Feeder Fund Expenses [Percent]" } } }, "localname": "OtherFeederFundExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherMasterFundExpensesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Master Fund Expenses [Percent]" } } }, "localname": "OtherMasterFundExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Securities [Table Text Block]" } } }, "localname": "OtherSecuritiesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherSecurityDescriptionTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Security, Description [Text Block]" } } }, "localname": "OtherSecurityDescriptionTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherSecurityTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Security, Title [Text Block]" } } }, "localname": "OtherSecurityTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherTransactionExpense1Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "order": 1.0, "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Transaction Expense 1 [Percent]" } } }, "localname": "OtherTransactionExpense1Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionExpense2Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "order": 2.0, "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Transaction Expense 2 [Percent]" } } }, "localname": "OtherTransactionExpense2Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionExpense3Percent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "order": 3.0, "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0 } }, "lang": { "en-us": { "role": { "label": "Other Transaction Expense 3 [Percent]" } } }, "localname": "OtherTransactionExpense3Percent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Expenses [Abstract]" } } }, "localname": "OtherTransactionExpensesAbstract", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_OtherTransactionExpensesPercent": { "auth_ref": [], "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "label": "Other Transaction Expenses [Percent]" } } }, "localname": "OtherTransactionExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionFeesBasisMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Maximum" } } }, "localname": "OtherTransactionFeesBasisMaximum", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_OtherTransactionFeesBasisMaximumPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Maximum [Percent]" } } }, "localname": "OtherTransactionFeesBasisMaximumPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_OtherTransactionFeesBasisNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Note [Text Block]" } } }, "localname": "OtherTransactionFeesBasisNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OtherTransactionFeesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Transaction Fees, Note [Text Block]" } } }, "localname": "OtherTransactionFeesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OutstandingSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Securities [Table Text Block]" } } }, "localname": "OutstandingSecuritiesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_OutstandingSecurityAuthorizedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Security, Authorized [Shares]" } } }, "localname": "OutstandingSecurityAuthorizedShares", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sharesItemType" }, "cef_OutstandingSecurityHeldShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Security, Held [Shares]" } } }, "localname": "OutstandingSecurityHeldShares", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sharesItemType" }, "cef_OutstandingSecurityNotHeldShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Security, Not Held [Shares]" } } }, "localname": "OutstandingSecurityNotHeldShares", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sharesItemType" }, "cef_OutstandingSecurityTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outstanding Security, Title [Text Block]" } } }, "localname": "OutstandingSecurityTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_PreferredStockRestrictionsArrearageTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Arrearage [Text Block]" } } }, "localname": "PreferredStockRestrictionsArrearageTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_PreferredStockRestrictionsOtherTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Other [Text Block]" } } }, "localname": "PreferredStockRestrictionsOtherTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_PrimaryShelfFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Primary Shelf [Flag]" } } }, "localname": "PrimaryShelfFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_PrimaryShelfQualifiedFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Primary Shelf Qualified [Flag]" } } }, "localname": "PrimaryShelfQualifiedFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_ProspectusLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prospectus [Line Items]" } } }, "localname": "ProspectusLineItems", "nsuri": "http://xbrl.sec.gov/cef/2022", "xbrltype": "stringItemType" }, "cef_ProspectusTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prospectus:" } } }, "localname": "ProspectusTable", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_PurposeOfFeeTableNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purpose of Fee Table , Note [Text Block]" } } }, "localname": "PurposeOfFeeTableNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_RegisteredClosedEndFundFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Registered Closed-End Fund [Flag]" } } }, "localname": "RegisteredClosedEndFundFlag", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "cef_ReturnAtMinusFivePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Minus Five [Percent]" } } }, "localname": "ReturnAtMinusFivePercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ReturnAtMinusTenPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Minus Ten [Percent]" } } }, "localname": "ReturnAtMinusTenPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ReturnAtPlusFivePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Plus Five [Percent]" } } }, "localname": "ReturnAtPlusFivePercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ReturnAtPlusTenPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Plus Ten [Percent]" } } }, "localname": "ReturnAtPlusTenPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_ReturnAtZeroPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Return at Zero [Percent]" } } }, "localname": "ReturnAtZeroPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_RightsLimitedByOtherSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rights Limited by Other Securities [Text Block]" } } }, "localname": "RightsLimitedByOtherSecuritiesTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_RightsSubjectToOtherThanMajorityVoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rights Subject to Other than Majority Vote [Text Block]" } } }, "localname": "RightsSubjectToOtherThanMajorityVoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_RiskAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risk [Axis]" } } }, "localname": "RiskAxis", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_RiskFactorsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risk Factors [Table Text Block]" } } }, "localname": "RiskFactorsTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_RiskTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risk [Text Block]" } } }, "localname": "RiskTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SalesLoadPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sales Load [Percent]" } } }, "localname": "SalesLoadPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_SecurityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security [Axis]" } } }, "localname": "SecurityAxis", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "cef_SecurityDividendsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Dividends [Text Block]" } } }, "localname": "SecurityDividendsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityLiabilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Liabilities [Text Block]" } } }, "localname": "SecurityLiabilitiesTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityLiquidationRightsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Liquidation Rights [Text Block]" } } }, "localname": "SecurityLiquidationRightsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityObligationsOfOwnershipTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Obligations of Ownership [Text Block]" } } }, "localname": "SecurityObligationsOfOwnershipTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityPreemptiveAndOtherRightsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Preemptive and Other Rights [Text Block]" } } }, "localname": "SecurityPreemptiveAndOtherRightsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Title [Text Block]" } } }, "localname": "SecurityTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SecurityVotingRightsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Voting Rights [Text Block]" } } }, "localname": "SecurityVotingRightsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Amount" } } }, "localname": "SeniorSecuritiesAmount", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_SeniorSecuritiesAverageMarketValuePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Average Market Value per Unit" } } }, "localname": "SeniorSecuritiesAverageMarketValuePerUnit", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_SeniorSecuritiesAveragingMethodNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Averaging Method, Note [Text Block]" } } }, "localname": "SeniorSecuritiesAveragingMethodNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesCoveragePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Coverage per Unit" } } }, "localname": "SeniorSecuritiesCoveragePerUnit", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_SeniorSecuritiesHeadingsNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Headings, Note [Text Block]" } } }, "localname": "SeniorSecuritiesHeadingsNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesHighlightsAnnualizedNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Highlights Annualized, Note [Text Block]" } } }, "localname": "SeniorSecuritiesHighlightsAnnualizedNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesHighlightsAuditedNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Highlights Audited, Note [Text Block]" } } }, "localname": "SeniorSecuritiesHighlightsAuditedNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities Involuntary Liquidating Preference per Unit" } } }, "localname": "SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "cef_SeniorSecuritiesNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities, Note [Text Block]" } } }, "localname": "SeniorSecuritiesNoteTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SeniorSecuritiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Securities [Table Text Block]" } } }, "localname": "SeniorSecuritiesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SharePriceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Price [Table Text Block]" } } }, "localname": "SharePriceTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_SharePricesNotActualTransactionsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Prices Not Actual Transactions [Text Block]" } } }, "localname": "SharePricesNotActualTransactionsTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_ShareholderTransactionExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholder Transaction Expenses [Table Text Block]" } } }, "localname": "ShareholderTransactionExpensesTableTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_TotalAnnualExpensesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total Annual Expenses [Percent]" } } }, "localname": "TotalAnnualExpensesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_UnderwritersCompensationPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Underwriters Compensation [Percent]" } } }, "localname": "UnderwritersCompensationPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_WaiversAndReimbursementsOfFeesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Waivers and Reimbursements of Fees [Percent]" } } }, "localname": "WaiversAndReimbursementsOfFeesPercent", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "percentItemType" }, "cef_WarrantsOrRightsCalledAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Amount" } } }, "localname": "WarrantsOrRightsCalledAmount", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "monetaryItemType" }, "cef_WarrantsOrRightsCalledPeriodDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Period [Date]" } } }, "localname": "WarrantsOrRightsCalledPeriodDate", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "dateItemType" }, "cef_WarrantsOrRightsCalledTitleTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Title" } } }, "localname": "WarrantsOrRightsCalledTitleTextBlock", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "textBlockItemType" }, "cef_WarrantsOrRightsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Exercise Price" } } }, "localname": "WarrantsOrRightsExercisePrice", "nsuri": "http://xbrl.sec.gov/cef/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "perShareItemType" }, "dei_AdditionalSecurities462b": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "localname": "AdditionalSecurities462b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_AdditionalSecurities462bFileNumber": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "localname": "AdditionalSecurities462bFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_AdditionalSecuritiesEffective413b": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "localname": "AdditionalSecuritiesEffective413b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings.", "label": "Approximate Date of Commencement of Proposed Sale to Public" } } }, "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "dateOrAsapItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r7", "r8" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "dei_DelayedOrContinuousOffering": { "auth_ref": [ "r9", "r10", "r14" ], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "localname": "DelayedOrContinuousOffering", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_DividendOrInterestReinvestmentPlanOnly": { "auth_ref": [ "r9", "r10", "r14" ], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "localname": "DividendOrInterestReinvestmentPlanOnly", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "submissionTypeItemType" }, "dei_EffectiveAfter60Days486a": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "localname": "EffectiveAfter60Days486a", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveOnDate486a": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "localname": "EffectiveOnDate486a", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "dateItemType" }, "dei_EffectiveOnDate486b": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "localname": "EffectiveOnDate486b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "dateItemType" }, "dei_EffectiveOnSetDate486a": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "localname": "EffectiveOnSetDate486a", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveOnSetDate486b": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "localname": "EffectiveOnSetDate486b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveUponFiling462e": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } }, "localname": "EffectiveUponFiling462e", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveUponFiling486b": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "localname": "EffectiveUponFiling486b", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EffectiveWhenDeclaredSection8c": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "localname": "EffectiveWhenDeclaredSection8c", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInvCompanyType": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product).", "label": "Entity Inv Company Type" } } }, "localname": "EntityInvCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "invCompanyType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "yesNoItemType" }, "dei_ExhibitsOnly462d": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "localname": "ExhibitsOnly462d", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_ExhibitsOnly462dFileNumber": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "localname": "ExhibitsOnly462dFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_InvestmentCompanyActFileNumber": { "auth_ref": [ "r10", "r11", "r12", "r13" ], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "localname": "InvestmentCompanyActFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_InvestmentCompanyActRegistration": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "localname": "InvestmentCompanyActRegistration", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_InvestmentCompanyRegistrationAmendment": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "localname": "InvestmentCompanyRegistrationAmendment", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "localname": "InvestmentCompanyRegistrationAmendmentNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sequenceNumberItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "normalizedStringItemType" }, "dei_NewEffectiveDateForPreviousFiling": { "auth_ref": [ "r10", "r11", "r12", "r13" ], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "localname": "NewEffectiveDateForPreviousFiling", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_NoSubstantiveChanges462c": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "localname": "NoSubstantiveChanges462c", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_NoSubstantiveChanges462cFileNumber": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "localname": "NoSubstantiveChanges462cFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "fileNumberItemType" }, "dei_PostEffectiveAmendment": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "localname": "PostEffectiveAmendment", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_PostEffectiveAmendmentNumber": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective.", "label": "Post-Effective Amendment Number" } } }, "localname": "PostEffectiveAmendmentNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sequenceNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreEffectiveAmendment": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "localname": "PreEffectiveAmendment", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "booleanItemType" }, "dei_PreEffectiveAmendmentNumber": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective.", "label": "Pre-Effective Amendment Number" } } }, "localname": "PreEffectiveAmendmentNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "xbrltype": "sequenceNumberItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.soligenix.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Form N-2", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form N-3", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form N-4", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form N-6", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form S-3", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Investment Company Act", "Number": "270", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "313", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "413", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r20": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "462", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r21": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "462", "Subsection": "c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r22": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "462", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r23": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "462", "Subsection": "e", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r24": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "486", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r25": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "486", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r26": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r27": { "Name": "Securities Act", "Publisher": "SEC", "Section": "8", "Subsection": "c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Form F-3", "Publisher": "SEC", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 19 0001558370-23-005925-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-005925-xbrl.zip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end